Online citations, reference lists, and bibliographies.
← Back to Search

Chapter 14 – Late Effects After Radiation

M. Milano, L. Marks, L. Constine
Published 2016 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
This paper references
10.1016/J.IJROBP.2007.01.010
Dosimetric predictors of laryngeal edema.
G. Sanguineti (2007)
10.1200/JCO.2002.09.126
Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study.
E. Shaw (2002)
10.1016/j.ijrobp.2007.10.052
Dose-volume parameters of the corpora cavernosa do not correlate with erectile dysfunction after external beam radiotherapy for prostate cancer: results from a dose-escalation trial.
Gerard J van der Wielen (2008)
10.1016/j.ijrobp.2009.01.062
Long-term toxicity following 3D conformal radiation therapy for prostate cancer from the RTOG 9406 phase I/II dose escalation study.
J. Michalski (2010)
10.1016/S0360-3016(01)01619-4
Relating radiation-induced regional lung injury to changes in pulmonary function tests.
M. Fan (2001)
10.1016/j.ijrobp.2012.03.024
Using generalized equivalent uniform dose atlases to combine and analyze prospective dosimetric and radiation pneumonitis data from 2 non-small cell lung cancer dose escalation protocols.
F. Liu (2013)
10.1016/S0360-3016(02)02805-5
Penile bulb imaging.
K. Wallner (2002)
10.1016/S0167-8140(02)00147-0
Relationships between DVHs and late rectal bleeding after radiotherapy for prostate cancer: analysis of a large group of patients pooled from three institutions.
C. Fiorino (2002)
10.1016/j.ijrobp.2009.03.079
Radiation dose-volume effects in the larynx and pharynx.
T. Rancati (2010)
10.1182/BLOOD-2006-07-034405
Late cardiotoxicity after treatment for Hodgkin lymphoma.
B. Aleman (2007)
10.1016/j.ijrobp.2012.09.036
Small bowel dose parameters predicting grade ≥ 3 acute toxicity in rectal cancer patients treated with neoadjuvant chemoradiation: an independent validation study comparing peritoneal space versus small bowel loop contouring techniques.
R. Banerjee (2013)
10.1016/J.IJROBP.2006.07.1337
Analysis of clinical and dosimetric factors associated with treatment-related pneumonitis (TRP) in patients with non-small-cell lung cancer (NSCLC) treated with concurrent chemotherapy and three-dimensional conformal radiotherapy (3D-CRT).
S. Wang (2006)
10.1016/0360-3016(93)90428-X
Accelerated hyperfractionated hepatic irradiation in the management of patients with liver metastases: results of the RTOG dose escalating protocol.
A. Russell (1993)
10.1016/j.ijrobp.2012.08.002
Is there a dose-response relationship for heart disease with low-dose radiation therapy?
Eugene Chung (2013)
10.1016/j.ijrobp.2009.10.002
Candidate dosimetric predictors of long-term swallowing dysfunction after oropharyngeal intensity-modulated radiotherapy.
D. Schwartz (2010)
10.1016/j.ijrobp.2009.08.058
Quantifying local radiation-induced lung damage from computed tomography.
G. Ghobadi (2010)
10.1088/0031-9155/54/21/006
Assessing correlations between the spatial distribution of the dose to the rectal wall and late rectal toxicity after prostate radiotherapy: an analysis of data from the MRC RT01 trial (ISRCTN 47772397).
F. Buettner (2009)
10.1016/J.IJROBP.2004.04.037
Regional differences in lung radiosensitivity after radiotherapy for non-small-cell lung cancer.
Y. Seppenwoolde (2004)
10.1016/S0360-3016(02)02829-8
Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial.
A. Pollack (2002)
10.1016/j.ijrobp.2009.04.094
Radiation dose-volume effects and the penile bulb.
M. Roach (2010)
10.1200/jco.1991.9.10.1922
A prospective comparison of neuropsychologic performance of children surviving leukemia who received 18-Gy, 24-Gy, or no cranial irradiation.
R. Mulhern (1991)
10.1159/000168288
Persisting renotubular sequelae after cisplatin in children and adolescents.
M. Bianchetti (1991)
10.1016/j.ijrobp.2008.02.048
Dose to larynx predicts for swallowing complications after intensity-modulated radiotherapy.
H. Caglar (2008)
10.1016/S0360-3016(02)03742-2
Late rectal toxicity: dose-volume effects of conformal radiotherapy for prostate cancer.
E. H. Huang (2002)
10.1016/J.IJROBP.2005.09.025
Radiation pneumonitis following concurrent accelerated hyperfractionated radiotherapy and chemotherapy for limited-stage small-cell lung cancer: Dose-volume histogram analysis and comparison with conventional chemoradiation.
K. Tsujino (2006)
10.1016/J.IJROBP.2006.03.034
Rectal bleeding, fecal incontinence, and high stool frequency after conformal radiotherapy for prostate cancer: normal tissue complication probability modeling.
S. Peeters (2006)
10.1016/J.IJROBP.2004.05.026
Penile bulb dose and impotence after three-dimensional conformal radiotherapy for prostate cancer on RTOG 9406: findings from a prospective, multi-institutional, phase I/II dose-escalation study.
M. Roach (2004)
10.1200/JCO.2008.20.6763
Single nucleotide polymorphism at rs1982073:T869C of the TGFbeta 1 gene is associated with the risk of radiation pneumonitis in patients with non-small-cell lung cancer treated with definitive radiotherapy.
Xianglin Yuan (2009)
10.3109/0284186X.2010.504736
Cardiac toxicity and radiation dose to the heart in definitive treated non-small cell lung cancer
T. Schytte (2010)
10.1016/S0360-3016(00)01414-0
Late rectal bleeding after conformal radiotherapy of prostate cancer. II. Volume effects and dose-volume histograms.
A. Jackson (2001)
10.1016/j.radonc.2008.02.005
Intensity-modulated radiation therapy (IMRT) for inoperable non-small cell lung cancer: the Memorial Sloan-Kettering Cancer Center (MSKCC) experience.
Sonal Sura (2008)
10.1016/S0360-3016(02)02711-6
Factors affecting risk of symptomatic temporal lobe necrosis: significance of fractional dose and treatment time.
A. Lee (2002)
10.1016/j.ijrobp.2009.06.092
Radiation-associated liver injury.
Charlie C. Pan (2010)
10.1016/J.IJROBP.2004.05.050
Dysphagia and aspiration after chemoradiotherapy for head-and-neck cancer: which anatomic structures are affected and can they be spared by IMRT?
A. Eisbruch (2004)
10.1001/JAMA.290.21.2831
Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of hodgkin lymphoma treated with radiation therapy.
Matthew C. Hull (2003)
10.1016/J.IJROBP.2006.12.071
Proton-beam therapy for olfactory neuroblastoma.
H. Nishimura (2007)
10.1016/S0360-3016(96)00295-7
Symptomatic coronary artery disease after mantle irradiation for Hodgkin's disease.
V. King (1996)
10.1016/J.IJROBP.2007.03.048
Neurocognitive function of patients with brain metastasis who received either whole brain radiotherapy plus stereotactic radiosurgery or radiosurgery alone.
H. Aoyama (2007)
10.1016/j.radonc.2012.04.016
Symptomatic cardiac toxicity is predicted by dosimetric and patient factors rather than changes in 18F-FDG PET determination of myocardial activity after chemoradiotherapy for esophageal cancer.
A. Konski (2012)
10.1016/S0360-3016(02)02915-2
Radiation-induced liver disease after three-dimensional conformal radiotherapy for patients with hepatocellular carcinoma: dosimetric analysis and implication.
J. Cheng (2002)
10.1016/0167-8140(94)90005-1
Radiation-induced injury to the visual pathway.
G. Jiang (1994)
10.1053/SRAO.2002.31360
Radiation pneumonitis and early circulatory cytokine markers.
Y. Chen (2002)
10.1016/0360-3016(86)90284-1
Renal complications secondary to radiation treatment of upper abdominal malignancies.
C. Willett (1986)
10.1007/s00066-012-0288-8
Dysphagia after definitive radiotherapy for head and neck cancer
L. Deantonio (2012)
10.1016/S0360-3016(97)00029-1
Dose-volume complication analysis for visual pathway structures of patients with advanced paranasal sinus tumors.
M. Martel (1997)
10.1186/1748-717X-4-52
Clinical-dosimetric analysis of measures of dysphagia including gastrostomy-tube dependence among head and neck cancer patients treated definitively by intensity-modulated radiotherapy with concurrent chemotherapy
B. Li (2009)
10.1097/IGC.0b013e318286aa68
Tolerance of the Small Bowel to Therapeutic Irradiation: A Focus on Late Toxicity in Patients Receiving Para-Aortic Nodal Irradiation for Gynecologic Malignancies
S. Stanić (2013)
10.1097/00130404-200201000-00011
Dose/volume relationship of late rectal bleeding after external beam radiotherapy for localized prostate cancer: absolute or relative rectal volume?
P. Kupelian (2002)
10.1016/j.ijrobp.2011.10.065
Change in diffusing capacity after radiation as an objective measure for grading radiation pneumonitis in patients treated for non-small-cell lung cancer.
J. L. Lopez Guerra (2012)
10.1259/BJR/37893924
Sparing of the penile bulb and proximal penile structures with intensity-modulated radiation therapy for prostate cancer.
J. Kao (2004)
10.1200/JCO.1992.10.9.1390
Whole-brain irradiation and decline in intelligence: the influence of dose and age on IQ score.
J. Silber (1992)
10.1016/S0360-3016(01)01631-5
Different risks of symptomatic brain necrosis in NPC patients treated with different altered fractionated radiotherapy techniques.
Y. Jen (2001)
10.1016/J.IJROBP.2005.12.002
Cerebral radiation necrosis: incidence, outcomes, and risk factors with emphasis on radiation parameters and chemotherapy.
J. Ruben (2006)
10.1016/J.IJROBP.2006.08.015
Dose-volumetric parameters predicting radiation-induced hepatic toxicity in unresectable hepatocellular carcinoma patients treated with three-dimensional conformal radiotherapy.
T. Kim (2007)
10.1016/j.ijrobp.2009.04.095
Radiation dose-volume effects in the spinal cord.
J. Kirkpatrick (2010)
10.1016/j.ijrobp.2012.07.2375
Validation of normal tissue complication probability predictions in individual patient: late rectal toxicity.
V. Semenenko (2013)
10.1016/S0360-3016(02)03986-X
Comparing different NTCP models that predict the incidence of radiation pneumonitis. Normal tissue complication probability.
Y. Seppenwoolde (2003)
10.1016/j.ijrobp.2013.05.049
Multivariate normal tissue complication probability modeling of heart valve dysfunction in Hodgkin lymphoma survivors.
L. Cella (2013)
10.1016/j.ijrobp.2009.03.078
Radiation dose-volume effects in radiation-induced rectal injury.
J. Michalski (2010)
10.1016/j.ijrobp.2007.11.044
Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer.
M. Zelefsky (2008)
10.1016/S0360-3016(02)02709-8
Improvement of local control of T3 and T4 nasopharyngeal carcinoma by hyperfractionated radiotherapy and concomitant chemotherapy.
J. Jian (2002)
10.1016/S0360-3016(03)00093-2
Dosimetric predictors of xerostomia for head-and-neck cancer patients treated with the smart (simultaneous modulated accelerated radiation therapy) boost technique.
C. Amosson (2003)
10.1016/J.IJROBP.2006.06.013
Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: initial report on a randomized controlled clinical trial.
E. H. Pow (2006)
10.1016/J.IJROBP.2004.07.715
Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy.
S. Peeters (2005)
10.1016/J.IJROBP.2004.05.048
Biologic susceptibility of hepatocellular carcinoma patients treated with radiotherapy to radiation-induced liver disease.
J. Cheng (2004)
10.1016/J.IJROBP.2006.12.031
Initial evaluation of treatment-related pneumonitis in advanced-stage non-small-cell lung cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy.
S. Yom (2007)
10.1016/J.RADONC.2004.02.009
Sensory neural hearing loss after concurrent cisplatin and radiation therapy for nasopharyngeal carcinoma.
Young-Taek Oh (2004)
10.1200/JCO.2007.11.5501
Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients.
M. Kam (2007)
10.1016/J.IJROBP.2004.12.015
Long-term parotid gland function after radiotherapy.
P. Braam (2005)
10.1016/j.ijrobp.2013.07.029
Predicting esophagitis after chemoradiation therapy for non-small cell lung cancer: an individual patient data meta-analysis.
D. Palma (2013)
10.1016/S0360-3016(02)04288-8
Do dose-volume metrics predict pulmonary function changes in lung irradiation?
A. Allen (2003)
10.1016/j.clon.2011.03.001
The impact of clinical factors on the development of late radiation toxicity: results from the Medical Research Council RT01 trial (ISRCTN47772397).
G. Barnett (2011)
10.1080/095530000138466
Radiation-induced pulmonary injury: symptomatic versus subclinical endpoints.
L. Marks (2000)
10.1016/j.ijrobp.2007.11.075
The radiation dose-response of the human spinal cord.
T. Schultheiss (2008)
10.1016/J.RADONC.2007.07.009
Dysphagia disorders in patients with cancer of the oropharynx are significantly affected by the radiation therapy dose to the superior and middle constrictor muscle: a dose-effect relationship.
P. Levendag (2007)
10.3748/WJG.V11.I17.2626
Clinical and dosimetric factors of radiation-induced esophageal injury: radiation-induced esophageal toxicity.
Wen-Bo Qiao (2005)
10.1007/s00066-012-0227-8
Erectile dysfunction after prostate three-dimensional conformal radiation therapy
A. Magli (2012)
10.1016/S0360-3016(02)02823-7
Intensity-modulated radiation therapy (IMRT) for meningioma.
N. Uy (2002)
10.1016/S0140-6736(02)11398-5
Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative study
M. Klein (2002)
10.1016/J.IJROBP.2003.10.058
Spinal cord tolerance to high-dose fractionated 3D conformal proton-photon irradiation as evaluated by equivalent uniform dose and dose volume histogram analysis.
L. Marucci (2004)
10.1016/0360-3016(84)90202-5
Unilateral radiation nephropathy--the long-term significance.
T. Kim (1984)
10.1016/j.ijrobp.2009.01.036
Adding ipsilateral V20 and V30 to conventional dosimetric constraints predicts radiation pneumonitis in stage IIIA-B NSCLC treated with combined-modality therapy.
S. Ramella (2010)
10.1016/0360-3016(93)90417-T
Renal tolerance to nonhomogenous irradiation: comparison of observed effects to predictions of normal tissue complication probability from different biophysical models.
M. Flentje (1993)
10.1002/1097-0142(19911101)68:9<1913::AID-CNCR2820680912>3.0.CO;2-2
Cognitive function in children with leukemia. Effect of radiation dose and time since irradiation
Ida Marie (Ki)Moore (1991)
10.1007/s00066-003-1078-0
A Little to a Lot or a Lot to a Little?
J. Willner (2003)
10.1016/S0360-3016(99)00560-X
Late rectal toxicity after conformal radiotherapy of prostate cancer (I): multivariate analysis and dose-response.
M. Skwarchuk (2000)
10.1016/S0360-3016(96)80015-0
A prospective study of cognitive functions following conventional radiotherapy for supratentorial gliomas in young adults: 4-year results.
M. C. Vigliani (1996)
10.1016/0360-3016(90)90393-X
Long-term psychological effects in children treated for intracranial tumors.
L. Jannoun (1990)
10.1016/0360-3016(77)90046-3
The relationship of time-dose fractionation factors to complications in the treatment of pituitary tumors by irradiation.
S. Aristizabal (1977)
10.1016/S0360-3016(00)00786-0
Final report of a randomized trial on altered-fractionated radiotherapy in nasopharyngeal carcinoma prematurely terminated by significant increase in neurologic complications.
P. Teo (2000)
10.1200/JCO.2003.04.172
Effects of radiotherapy on cognitive function in patients with low-grade glioma measured by the folstein mini-mental state examination.
P. Brown (2003)
10.1016/j.ijrobp.2009.02.089
Radiation-associated kidney injury.
L. Dawson (2010)
10.1016/0167-8140(88)90253-8
Quantitative measurement of changes in human lung density following irradiation.
K. Mah (1988)
10.1016/j.radonc.2010.09.013
Why avoid the hippocampus? A comprehensive review.
V. Gondi (2010)
10.1016/J.RADONC.2007.06.004
Late swallowing dysfunction and dysphagia after radiotherapy for pharynx cancer: frequency, intensity and correlation with dose and volume parameters.
K. Jensen (2007)
10.1016/S0360-3016(00)01411-5
Benign meningioma: partially resected, biopsied, and recurrent intracranial tumors treated with combined proton and photon radiotherapy.
E. Wenkel (2000)
10.1016/J.IJROBP.2003.12.028
Erectile dysfunction and radiation dose to penile base structures: a lack of correlation.
U. Selek (2004)
10.1016/S0360-3016(03)00665-5
Rectal dose-volume constraints in high-dose radiotherapy of localized prostate cancer.
C. Fiorino (2003)
10.1016/j.ijrobp.2009.02.017
Dosimetric factors associated with long-term dysphagia after definitive radiotherapy for squamous cell carcinoma of the head and neck.
J. Caudell (2010)
10.1016/J.IJROBP.2006.01.051
Final toxicity results of a radiation-dose escalation study in patients with non-small-cell lung cancer (NSCLC): predictors for radiation pneumonitis and fibrosis.
F. Kong (2006)
10.1007/s00432-012-1284-1
Prediction of radiation pneumonitis in lung cancer patients: a systematic review
X. Zhang (2012)
10.1530/EJE-11-0749
Cognitive performance after postoperative pituitary radiotherapy: a dosimetric study of the hippocampus and the prefrontal cortex.
P. Brummelman (2012)
10.1016/j.ijrobp.2010.07.1990
Impact of salivary gland dosimetry on post-IMRT recovery of saliva output and xerostomia grade for head-and-neck cancer patients treated with or without contralateral submandibular gland sparing: a longitudinal study.
Z. Wang (2011)
10.1016/S0360-3016(01)01717-5
Qantitative dose-volume response analysis of changes in parotid gland function after radiotheraphy in the head-and-neck region
J. Roesink (2001)
10.1016/J.IJROBP.2003.09.086
Dose and volume reduction for normal lung using intensity-modulated radiotherapy for advanced-stage non-small-cell lung cancer.
H. Murshed (2004)
10.1016/S0360-3016(02)03807-5
Predictive value of dose-volume histogram parameters for predicting radiation pneumonitis after concurrent chemoradiation for lung cancer.
K. Tsujino (2003)
10.1016/J.IJROBP.2006.09.012
Prospective study on late renal toxicity following postoperative chemoradiotherapy in gastric cancer.
E. Jansen (2007)
10.1016/S0735-1097(03)00759-9
Asymptomatic cardiac disease following mediastinal irradiation.
P. Heidenreich (2003)
10.1016/S0167-8140(02)00013-0
Preservation of parotid function with uncomplicated conformal radiotherapy.
A. Maes (2002)
Final report of the 70.2-Gy and 75.6-Gy dose levels of a phase I dose escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable non-small cell lung cancer.
K. Rosenzweig (2000)
10.1007/s00268-003-7105-6
Salivary Gland Sparing and Improved Target Irradiation by Conformal and Intensity Modulated Irradiation of Head and Neck Cancer
A. Eisbruch (2003)
10.1016/S0360-3016(01)01634-0
Combination of photon and proton radiation therapy for chordomas and chondrosarcomas of the skull base: the Centre de Protonthérapie D'Orsay experience.
G. Noël (2001)
10.1016/S0360-3016(03)00184-6
Risk of long-term complications after TFG-beta1-guided very-high-dose thoracic radiotherapy.
M. Anscher (2003)
10.1016/S0360-3016(02)03986-X
Biology contributionComparing different NTCP models that predict the incidence of radiation pneumonitis
Y. Seppenwoolde (2003)
10.1016/0360-3016(94)90184-8
Late complications of postoperative radiation therapy for cancer of the rectum and rectosigmoid.
A. C. Mak (1994)
10.1016/S0360-3016(00)01441-3
A prospective study of salivary function sparing in patients with head-and-neck cancers receiving intensity-modulated or three-dimensional radiation therapy: initial results.
K. Chao (2001)
10.1016/j.ijrobp.2012.01.023
Pelvic normal tissue contouring guidelines for radiation therapy: a Radiation Therapy Oncology Group consensus panel atlas.
H. Gay (2012)
10.1200/JCO.1998.16.5.1723
Neuropsychologic functioning of survivors of childhood medulloblastoma randomized to receive conventional or reduced-dose craniospinal irradiation: a Pediatric Oncology Group study.
R. Mulhern (1998)
10.1016/J.IJROBP.2006.06.025
Impact of patient-specific factors, irradiated left ventricular volume, and treatment set-up errors on the development of myocardial perfusion defects after radiation therapy for left-sided breast cancer.
E. S. Evans (2006)
10.1016/J.RADONC.2003.05.001
A dosimetric analysis of acute gastrointestinal toxicity in women receiving intensity-modulated whole-pelvic radiation therapy.
J. Roeske (2003)
10.3109/0284186X.2010.521192
Heart irradiation as a risk factor for radiation pneumonitis
E. Huang (2011)
10.1016/j.ijrobp.2009.02.091
Radiation dose-volume effects in the brain.
Y. Lawrence (2010)
10.1016/J.IJROBP.2006.09.021
The impact of dose on parotid salivary recovery in head and neck cancer patients treated with radiation therapy.
Y. Li (2007)
10.1159/000061211
Dose-volume tolerance of the brainstem after high-dose radiotherapy.
J. Debus (1999)
10.1016/j.ijrobp.2010.11.047
Radiation-induced middle ear and mastoid opacification in skull base tumors treated with radiotherapy.
G. Walker (2011)
10.1016/S0360-3016(99)00183-2
Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC)
M. Graham (1999)
10.1016/j.ijrobp.2010.03.058
An improved model for predicting radiation pneumonitis incorporating clinical and dosimetric variables.
P. Jenkins (2011)
10.1093/neuonc/nos303
Association between radiation dose to neuronal progenitor cell niches and temporal lobes and performance on neuropsychological testing in children: a prospective study.
K. Redmond (2013)
10.1212/WNL.59.1.40
Late cognitive and radiographic changes related to radiotherapy: Initial prospective findings
C. Armstrong (2002)
10.1016/S0360-3016(01)01685-6
Radiation-induced pulmonary toxicity: a dose-volume histogram analysis in 201 patients with lung cancer.
M. L. Hernando (2001)
10.1038/bjc.2012.575
Radiation-related mortality from heart disease and lung cancer more than 20 years after radiotherapy for breast cancer
K. Henson (2013)
10.1016/J.IJROBP.2006.03.032
A prospective study on radiation-induced changes in hearing function.
F. Herrmann (2006)
10.1016/J.RADONC.2006.02.017
Sparing of the submandibular glands by intensity modulated radiotherapy in the treatment of head and neck cancer.
K. Saarilahti (2006)
10.1016/j.ijrobp.2012.04.043
Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis.
D. Palma (2013)
10.1016/J.IJROBP.2004.11.029
Pulmonary function changes after radiotherapy in non-small-cell lung cancer patients with long-term disease-free survival.
G. Borst (2005)
10.1016/j.ijrobp.2012.10.004
Duodenal and other gastrointestinal toxicity in cervical and endometrial cancer treated with extended-field intensity modulated radiation therapy to paraaortic lymph nodes.
Philip D. Poorvu (2013)
10.1097/COC.0b013e318261054e
Submandibular Gland-sparing Intensity-modulated Radiotherapy
W. Mendenhall (2014)
10.1016/j.radonc.2011.08.009
Predictive modelling for swallowing dysfunction after primary (chemo)radiation: results of a prospective observational study.
Miranda E. Christianen (2012)
10.1016/j.ijrobp.2011.04.020
Treatment planning constraints to avoid xerostomia in head-and-neck radiotherapy: an independent test of QUANTEC criteria using a prospectively collected dataset.
V. Moiseenko (2012)
10.1002/(SICI)1097-0142(19980101)82:1<208::AID-CNCR26>3.0.CO;2-5
A comparative study of the long term psychosocial functioning of childhood acute lymphoblastic leukemia survivors treated by intrathecal methotrexate with or without cranial radiation
J. M. Hill (1998)
10.1016/j.radonc.2012.03.004
NTCP models for patient-rated xerostomia and sticky saliva after treatment with intensity modulated radiotherapy for head and neck cancer: the role of dosimetric and clinical factors.
I. Beetz (2012)
10.1186/1748-717X-3-36
Normal tissue toxicity after small field hypofractionated stereotactic body radiation
M. Milano (2008)
10.1038/sj.pcan.4500938
An analysis of erectile function after intensity modulated radiation therapy for localized prostate carcinoma
M. Brown (2007)
10.1200/JCO.2008.21.2738
Late effects of conformal radiation therapy for pediatric patients with low-grade glioma: prospective evaluation of cognitive, endocrine, and hearing deficits.
Thomas E. Merchant (2009)
10.1016/S0360-3016(98)00196-5
Radiation pneumonitis as a function of mean lung dose: an analysis of pooled data of 540 patients.
S. L. Kwa (1998)
10.1016/S0360-3016(97)00013-8
Quantification of radiation-induced regional lung injury with perfusion imaging.
L. Marks (1997)
10.1016/J.IJROBP.2005.04.016
Cognitive function after radiotherapy for supratentorial low-grade glioma: a North Central Cancer Treatment Group prospective study.
N. Laack (2005)
10.1016/j.ijrobp.2010.11.079
Functional polymorphisms of base excision repair genes XRCC1 and APEX1 predict risk of radiation pneumonitis in patients with non-small cell lung cancer treated with definitive radiation therapy.
M. Yin (2011)
10.1016/J.IJROBP.2013.10.005
Memory Preservation With Conformal Avoidance of the Hippocampus During Whole-Brain Radiation Therapy for Patients With Brain Metastases: Primary Endpoint Results of RTOG 0933
V. Gondi (2013)
10.1016/0360-3016(95)00118-I
Time course and incidence of late complications in patients treated with radiation therapy for FIGO stage IB carcinoma of the uterine cervix.
P. Eifel (1995)
10.1016/J.IJROBP.2006.03.063
Clinical dose-volume histogram analysis in predicting radiation pneumonitis in Hodgkin's lymphoma.
Eng-Siew Koh (2006)
10.1016/j.ijrobp.2010.09.058
Late toxicity after intensity-modulated radiation therapy for localized prostate cancer: an exploration of dose-volume histogram parameters to limit genitourinary and gastrointestinal toxicity.
A. Pederson (2012)
10.1016/J.IJROBP.2004.07.708
Coronary heart disease after radiotherapy for peptic ulcer disease.
Zhanat A Carr (2005)
10.1016/J.IJROBP.2004.05.030
Radiation dose delivered to the proximal penis as a predictor of the risk of erectile dysfunction after three-dimensional conformal radiotherapy for localized prostate cancer.
A. Wernicke (2004)
10.1016/S0360-3016(99)00163-7
Clinical and dosimetric predictors of radiation-induced esophageal toxicity.
P. D. Maguire (1999)
10.1016/J.IJROBP.2004.12.052
Dose-volume analysis of predictors for chronic rectal toxicity after treatment of prostate cancer with adaptive image-guided radiotherapy.
C. Vargas (2005)
10.1016/S0360-3016(02)03937-8
Predictors of radiation-induced esophageal toxicity in patients with non-small-cell lung cancer treated with three-dimensional conformal radiotherapy.
A. Singh (2003)
10.1016/S0360-3016(03)00182-2
Long-term changes in pulmonary function tests after definitive radiotherapy for lung cancer.
K. L. Miller (2003)
10.1016/j.radonc.2011.05.010
Development of NTCP models for head and neck cancer patients treated with three-dimensional conformal radiotherapy for xerostomia and sticky saliva: the role of dosimetric and clinical factors.
I. Beetz (2012)
10.1016/j.radonc.2011.01.021
Association between single nucleotide polymorphisms in the gene for XRCC1 and radiation-induced late toxicity in prostate cancer patients.
T. Langsenlehner (2011)
10.1016/0360-3016(91)90171-Y
Tolerance of normal tissue to therapeutic irradiation.
B. Emami (1991)
10.1097/00041327-200409000-00003
Lack of Radiation Optic Neuropathy in 72 Patients Treated for Pituitary Adenoma
A. V. D. van den Bergh (2004)
10.3109/0284186X.2012.718093
A literature-based meta-analysis of clinical risk factors for development of radiation induced pneumonitis
I. Vogelius (2012)
10.1186/1748-717X-8-11
Dosimetric parameter predicting the deterioration of hepatic function after helical tomotherapy in patients with unresectable locally advanced hepatocellular carcinoma
S. Son (2013)
10.1016/j.ijrobp.2011.11.073
Do intermediate radiation doses contribute to late rectal toxicity? An analysis of data from radiation therapy oncology group protocol 94-06.
S. Tucker (2012)
10.1016/0169-5002(94)91685-3
Toxicity of thoracic radiotherapy on pulmonary function in lung cancer.
N. Choi (1994)
10.1016/j.ijrobp.2008.11.041
Dysphagia after chemoradiotherapy for head-and-neck squamous cell carcinoma: dose-effect relationships for the swallowing structures.
P. Dirix (2009)
10.1016/j.ijrobp.2011.09.022
Dose-volume analysis of predictors for gastrointestinal toxicity after concurrent full-dose gemcitabine and radiotherapy for locally advanced pancreatic adenocarcinoma.
Jiayi Huang (2012)
10.1016/J.IJROBP.2007.07.189
Neurocognitive Impact of Whole Brain Radiation on Patients With Brain Metastases: Secondary Analysis of RTOG BR-0018
Y. Kwok (2007)
10.1120/jacmp.v12i2.3368
Dose tolerance limits and dose volume histogram evaluation for stereotactic body radiotherapy
J. Grimm (2011)
10.1016/j.ijrobp.2010.04.021
Association between pulmonary uptake of fluorodeoxyglucose detected by positron emission tomography scanning after radiation therapy for non-small-cell lung cancer and radiation pneumonitis.
M. M. Mac Manus (2011)
10.1002/PBC.20011
Influence of Age Upon Ifosfamide‐Induced Nephrotoxicity
J. McCune (2004)
10.1016/S0360-3016(02)02846-8
Analysis of radiation-induced liver disease using the Lyman NTCP model.
L. Dawson (2002)
10.1016/J.RADONC.2004.09.015
Dose-response relationships within the parotid gland after radiotherapy for head and neck cancer.
B. Bussels (2004)
10.1016/J.IJROBP.2006.03.014
Three-dimensional conformal radiotherapy for locally advanced (Stage II and worse) head-and-neck cancer: dosimetric and clinical evaluation.
M. Portaluri (2006)
10.1016/j.ijrobp.2008.05.040
Relative contributions of radiation and cisplatin-based chemotherapy to sensorineural hearing loss in head-and-neck cancer patients.
Y. Hitchcock (2009)
10.1016/j.ijrobp.2012.02.034
A phase II study of submandibular gland transfer prior to radiation for prevention of radiation-induced xerostomia in head-and-neck cancer (RTOG 0244).
N. Jha (2012)
10.1016/S0360-3016(96)00468-3
Late GI and GU complications in the treatment of prostate cancer.
T. Schultheiss (1997)
10.1016/j.ijrobp.2009.02.032
Influence of technologic advances on outcomes in patients with unresectable, locally advanced non-small-cell lung cancer receiving concomitant chemoradiotherapy.
Z. Liao (2010)
10.1016/J.IJROBP.2006.08.039
Intensity-modulated radiotherapy for pituitary adenomas: the preliminary report of the Cleveland Clinic experience.
H. Mackley (2007)
10.1016/S0161-6420(85)33898-8
Radiation optic neuropathy.
L. Kline (1985)
10.1016/S1474-4422(09)70204-2
Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up
L. Douw (2009)
10.1016/j.ijrobp.2009.08.078
Radiation associated brainstem injury.
C. Mayo (2010)
10.1016/J.IJROBP.2006.07.1389
Intensity-modulated radiation therapy for malignancies of the nasal cavity and paranasal sinuses.
M. Daly (2007)
10.1016/J.IJROBP.2005.01.029
The incidence and functional consequences of RT-associated cardiac perfusion defects.
L. Marks (2005)
10.1148/RADIOL.2351040248
Dose-volumetric parameters for predicting severe radiation pneumonitis after three-dimensional conformal radiation therapy for lung cancer.
T. Kim (2005)
10.1016/J.IJROBP.2004.06.014
Dosimetric and clinical predictors for radiation-induced esophageal injury.
S. Ahn (2005)
10.1016/J.IJROBP.2006.03.012
Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma.
A. Allen (2006)
10.1186/1748-717X-5-99
Reduction of radiation pneumonitis by V20-constraints in breast cancer
U. Goldman (2010)
10.1016/J.IJROBP.2004.08.019
Prospective study of inner ear radiation dose and hearing loss in head-and-neck cancer patients.
C. Pan (2005)
10.1016/S0360-3016(97)00364-7
Brainstem tolerance to conformal radiotherapy of skull base tumors.
J. Debus (1997)
10.1016/S1040-8428(01)00227-X
Radiation-associated cardiovascular disease.
M. Adams (2003)
10.1016/S0360-3016(01)01512-7
Xerostomia and its predictors following parotid-sparing irradiation of head-and-neck cancer.
A. Eisbruch (2001)
10.1007/s00066-012-0257-2
Xerostomia after radiotherapy
S. Tribius (2012)
10.1148/120.1.167
Visual complications following irradiation for pituitary adenomas and craniopharyngiomas.
J. Harris (1976)
10.1016/S0167-8140(96)91782-X
Neuropsychometric evaluation of long-term survivors of adult brain tumours: relationship with tumour and treatment parameters.
A. Gregor (1996)
10.1016/J.IJROBP.2004.12.009
Does altered fractionation influence the risk of radiation-induced optic neuropathy?
N. Bhandare (2005)
10.1016/j.ijrobp.2007.11.011
Intensity-modulated radiotherapy for resected mesothelioma: the Duke experience.
E. Miles (2008)
10.1200/JCO.2001.19.15.3470
Intellectual outcome after reduced-dose radiation therapy plus adjuvant chemotherapy for medulloblastoma: a Children's Cancer Group study.
M. Ris (2001)
10.1016/J.IJROBP.2006.09.030
Incidence of radiation pneumonitis after thoracic irradiation: Dose-volume correlates.
J. Schallenkamp (2007)
10.1002/cncr.21683
Sensorineural hearing loss in combined modality treatment of nasopharyngeal carcinoma
W. Chen (2006)
10.1016/J.IJROBP.2004.07.712
Comparison of rectal dose-wall histogram versus dose-volume histogram for modeling the incidence of late rectal bleeding after radiotherapy.
S. Tucker (2004)
10.1111/J.1442-2050.2005.00523.X
Cardiac function after chemoradiation for esophageal cancer: comparison of heart dose-volume histogram parameters to multiple gated acquisition scan changes.
P. Tripp (2005)
10.1016/j.ijrobp.2011.10.021
Hippocampal dosimetry predicts neurocognitive function impairment after fractionated stereotactic radiotherapy for benign or low-grade adult brain tumors.
V. Gondi (2012)
10.1016/S0360-3016(03)01437-8
Evaluation of salivary gland function after treatment of head-and-neck tumors with intensity-modulated radiotherapy by quantitative pertechnetate scintigraphy.
M. Muenter (2004)
10.1038/nrclinonc.2013.59
Breast cancer: Risk of heart disease after radiotherapy—cause for concern
T. Zagar (2013)
10.1200/JCO.2005.01.7145
Early variations of circulating interleukin-6 and interleukin-10 levels during thoracic radiotherapy are predictive for radiation pneumonitis.
D. Arpin (2005)
10.1002/1097-0142(20010701)92:1<15::AID-CNCR1286>3.0.CO;2-W
Excellent therapeutic efficacy and minimal late neurotoxicity in children treated with 18 grays of cranial radiation therapy for high‐risk acute lymphoblastic leukemia
D. Waber (2001)
10.1200/JCO.2001.19.1.127
Dose escalation in non-small-cell lung cancer using three-dimensional conformal radiation therapy: update of a phase I trial.
J. Hayman (2001)
10.1212/01.WNL.0000055862.20003.4A
A longitudinal neuropsychological study of partial brain radiation in adults with brain tumors
I. Torres (2003)
10.1016/S0360-3016(03)01031-9
Analysis of radiation-induced gastric and duodenal bleeds using the Lyman-Kutcher-Burman model
C. Pan (2003)
10.1016/j.ijrobp.2009.07.1754
Use of normal tissue complication probability models in the clinic.
L. Marks (2010)
10.1016/0360-3016(92)90651-W
The use of 3-D dose volume analysis to predict radiation hepatitis.
T. Lawrence (1991)
10.1016/j.ijrobp.2013.05.003
Effect of normal lung definition on lung dosimetry and lung toxicity prediction in radiation therapy treatment planning.
Weili Wang (2013)
10.1016/S0360-3016(98)00037-6
Estimation of the incidence of late bladder and rectum complications after high-dose (70-78 GY) conformal radiotherapy for prostate cancer, using dose-volume histograms.
L. Boersma (1998)
10.1016/j.ijrobp.2009.04.096
Radiation therapy and hearing loss.
N. Bhandare (2010)
10.1053/SRAO.2002.31359
Protection of salivary function by intensity-modulated radiation therapy in patients with head and neck cancer.
K. Chao (2002)
10.1016/J.IJROBP.2004.10.042
"Anatomically-correct" dosimetric parameters may be better predictors for esophageal toxicity than are traditional CT-based metrics.
D. Kahn (2005)
10.1016/j.ijrobp.2013.04.046
Coronary artery disease and breast radiation therapy.
R. Pezner (2013)
10.1016/J.IJROBP.2005.04.023
A comparison of mean parotid gland dose with measures of parotid gland function after radiotherapy for head-and-neck cancer: implications for future trials.
J. Roesink (2005)
10.1016/J.IJROBP.2004.12.076
Dose-volume modeling of salivary function in patients with head-and-neck cancer receiving radiotherapy.
A. Blanco (2005)
10.1016/J.IJROBP.2004.08.025
Dose-volume histogram analysis as predictor of radiation pneumonitis in primary lung cancer patients treated with radiotherapy.
M. Fay (2005)
10.1038/bjc.1996.145
Risk factors for intellectual and educational sequelae of cranial irradiation in childhood acute lymphoblastic leukaemia.
E. Smibert (1996)
10.1016/j.ijrobp.2009.05.070
Radiation dose-volume effects in the esophagus.
M. Werner-wasik (2010)
10.1016/J.IJROBP.2007.04.077
A nomogram to predict radiation pneumonitis, derived from a combined analysis of RTOG 9311 and institutional data.
J. Bradley (2007)
10.1016/j.ijrobp.2009.06.090
Radiotherapy dose-volume effects on salivary gland function.
J. Deasy (2010)
10.1016/j.ijrobp.2008.08.007
Conformal arc radiotherapy for prostate cancer: increased biochemical failure in patients with distended rectum on the planning computed tomogram despite image guidance by implanted markers.
B. Engels (2009)
10.1016/0959-8049(93)90214-Z
Compensatory renal response after unilateral partial and whole volume high-dose irradiation of the human kidney.
L. Dewit (1993)
10.1016/S0360-3016(97)00584-1
Fraction size and dose parameters related to the incidence of pericardial effusions.
M. Martel (1998)
10.1016/0360-3016(94)90346-8
Radiation optic neuropathy after megavoltage external-beam irradiation: analysis of time-dose factors.
J. T. Parsons (1994)
10.1016/j.ijrobp.2013.03.020
A novel method for predicting late genitourinary toxicity after prostate radiation therapy and the need for age-based risk-adapted dose constraints.
A. Ahmed (2013)
10.1001/JAMA.1993.03510160067031
Factors affecting late mortality from heart disease after treatment of Hodgkin's disease.
S. Hancock (1993)
10.1097/01.coc.0000158826.88179.75
Late Xerostomia After Intensity-Modulated Radiation Therapy Versus Conventional Radiotherapy
H. Pacholke (2005)
10.1016/J.IJROBP.2005.02.023
Results of spot-scanning proton radiation therapy for chordoma and chondrosarcoma of the skull base: the Paul Scherrer Institut experience.
D. Weber (2005)
10.1053/SRAO.2001.23483
Partial irradiation of the heart.
G. Gagliardi (2001)
10.1016/j.ijrobp.2012.03.052
Predicting pneumonitis risk: a dosimetric alternative to mean lung dose.
S. Tucker (2013)
10.1016/0167-8140(88)90299-X
Late radiation injuries of the gastrointestinal tract in the H2 and H5 EORTC Hodgkin's disease trials: emphasis on the role of exploratory laparotomy and fractionation.
J. M. Cosset (1988)
10.1016/j.ijrobp.2007.10.056
Risk factors for pericardial effusion in inoperable esophageal cancer patients treated with definitive chemoradiation therapy.
Xiong Wei (2008)
10.1016/j.ijrobp.2008.07.034
Sensorineural hearing loss after treatment of nasopharyngeal carcinoma: a longitudinal analysis.
S. H. Chan (2009)
10.1016/J.RADONC.2006.07.037
Evaluating the relationship between erectile dysfunction and dose received by the penile bulb: using data from a randomised controlled trial of conformal radiotherapy in prostate cancer (MRC RT01, ISRCTN47772397).
S. Mangar (2006)
10.1016/J.IJROBP.2005.10.002
Localized volume effects for late rectal and anal toxicity after radiotherapy for prostate cancer.
S. Peeters (2006)
10.1016/j.ijrobp.2009.06.091
Radiation dose-volume effects in the lung.
L. Marks (2010)
10.1259/0007-1285-69-825-839
Long-term cardiac mortality after radiotherapy of breast cancer--application of the relative seriality model.
G. Gagliardi (1996)
10.1016/S0360-3016(02)04389-4
Pulmonary function following high-dose radiotherapy of non-small-cell lung cancer.
K. de Jaeger (2003)
10.1002/1097-0142(19941115)74:10<2828::AID-CNCR2820741014>3.0.CO;2-K
White matter changes are correlated significantly with radiation dose. Observations from a randomized dose‐escalation trial for malignant glioma (radiation therapy oncology group 83‐02)
B. Corn (1994)
10.1093/jrr/rrt025
Preliminary analysis of risk factors for late rectal toxicity after helical tomotherapy for prostate cancer
N. Tomita (2013)
10.1016/S1470-2045(10)70290-4
Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial
C. Nutting (2011)
10.1016/j.ijrobp.2011.05.078
Predictive factors for radiation pneumonitis in Hodgkin lymphoma patients receiving combined-modality therapy.
A. M. Fox (2012)
10.1016/S0360-3016(02)04117-2
Significant correlation between rectal DVH and late bleeding in patients treated after radical prostatectomy with conformal or conventional radiotherapy (66.6-70.2 Gy).
C. Cozzarini (2003)
10.1016/J.IJROBP.2006.09.017
Ototoxicity after radiotherapy for head and neck tumors.
N. Bhandare (2007)
10.1155/2010/907960
Lhermitte's Sign Developing after IMRT for Head and Neck Cancer
D. C. Lim (2010)
10.1016/j.ijrobp.2007.10.010
Patterns of failure and toxicity after intensity-modulated radiotherapy for head and neck cancer.
Gordon O. Schoenfeld (2008)
10.1016/S0360-3016(01)01820-X
The dose-volume realationship of acute small bowel toxicity from concurrent 5-FU-based chemotherapy and radiation therapy for rectal cancer
K. Baglan (2002)
10.1016/S0360-3016(02)02929-2
Dose-volume factors contributing to the incidence of radiation pneumonitis in non-small-cell lung cancer patients treated with three-dimensional conformal radiation therapy.
E. Yorke (2002)
10.1016/S0360-3016(97)00341-6
A randomized phase III study of accelerated hyperfractionation versus standard in patients with unresected brain metastases: a report of the Radiation Therapy Oncology Group (RTOG) 9104.
K. Murray (1997)
10.1200/JCO.2001.19.2.543
Can we predict radiation-induced changes in pulmonary function based on the sum of predicted regional dysfunction?
M. Fan (2001)
10.1002/hed.20426
Permanent unilateral hearing loss after radiotherapy for parotid gland tumors
L. van der Putten (2006)
10.1097/01.coc.0000217828.95729.b5
The Potential Nephrotoxic Effects of Intensity Modulated Radiotherapy Delivered to the Para-Aortic Area of Women With Gynecologic Malignancies: Preliminary Results
J. Varlotto (2006)
10.1016/J.IJROBP.2004.06.260
Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma.
J. Bradley (2005)
10.1016/j.ijrobp.2009.07.1675
ATM polymorphisms are associated with risk of radiation-induced pneumonitis.
L. Zhang (2010)
10.1016/j.ijrobp.2012.07.003
Long-term changes in pulmonary function after incidental lung irradiation for breast cancer: a prospective study with 7-year follow-up.
J. Jaén (2012)
10.1016/J.IJROBP.2007.02.049
Intensity-modulated radiotherapy of head and neck cancer aiming to reduce dysphagia: early dose-effect relationships for the swallowing structures.
F. Feng (2007)
10.1016/j.ijrobp.2012.09.035
Duodenal toxicity after fractionated chemoradiation for unresectable pancreatic cancer.
P. Kelly (2013)
10.1016/S0360-3016(97)00580-4
Effect of time, dose, and fractionation on temporal lobe necrosis following radiotherapy for nasopharyngeal carcinoma.
A. Lee (1998)
10.1016/S0360-3016(97)00343-X
Physical and biological predictors of changes in whole-lung function following thoracic irradiation.
L. Marks (1997)
10.1016/S0167-8140(02)00173-1
Sensori-neural hearing loss after radiotherapy for nasopharyngeal carcinoma: individualized risk estimation.
H. Honoré (2002)
10.1016/j.ijrobp.2009.02.090
Radiation dose-volume effects of the urinary bladder.
A. Viswanathan (2010)
10.1016/j.ijrobp.2009.07.1753
Radiation dose-volume effects of optic nerves and chiasm.
C. Mayo (2010)
10.1016/S0360-3016(99)00247-3
Dose, volume, and function relationships in parotid salivary glands following conformal and intensity-modulated irradiation of head and neck cancer.
A. Eisbruch (1999)
10.1016/j.radonc.2013.03.021
A predictive model for dysphagia following IMRT for head and neck cancer: introduction of the EMLasso technique.
K. De Ruyck (2013)
10.1016/j.ijrobp.2009.05.071
Radiation dose-volume effects in the stomach and small bowel.
B. Kavanagh (2010)
10.1016/S0167-8140(00)00166-3
Long-term cardiac mortality following radiation therapy for Hodgkin's disease: analysis with the relative seriality model.
F. Eriksson (2000)
10.1056/NEJMoa1209825
Risk of ischemic heart disease in women after radiotherapy for breast cancer.
S. Darby (2013)
10.1200/JCO.2011.34.5900
Distribution of coronary artery stenosis after radiation for breast cancer.
G. Nilsson (2012)
10.1016/J.IJROBP.2007.05.021
Renal toxicity of adjuvant chemoradiotherapy with cisplatin in gastric cancer.
S. Welz (2007)
10.1002/lary.23735
Radiation fibrosis of the vocal fold: From man to mouse
M. Johns (2012)
10.1016/J.IJROBP.2007.03.011
Dose-dependent pulmonary toxicity after postoperative intensity-modulated radiotherapy for malignant pleural mesothelioma.
D. Rice (2007)
10.1016/S0167-8140(97)01907-5
Promising survival with three-dimensional conformal radiation therapy for non-small cell lung cancer.
J. Armstrong (1997)
10.1007/s00066-011-0010-2
Lhermitte sign and myelopathy after irradiation of the cervical spinal cord in radiotherapy treatment of head and neck cancer
V.E.M. Mul (2011)
10.1200/JCO.2012.48.2315
Neurocognitive outcomes decades after treatment for childhood acute lymphoblastic leukemia: a report from the St Jude lifetime cohort study.
K. Krull (2013)
10.1016/J.RADONC.2005.10.002
Does radiation dose to the salivary glands and oral cavity predict patient-rated xerostomia and sticky saliva in head and neck cancer patients treated with curative radiotherapy?
A. P. Jellema (2005)
10.1016/J.LUNGCAN.2003.09.015
Results following treatment to doses of 92.4 or 102.9 Gy on a phase I dose escalation study for non-small cell lung cancer.
S. Narayan (2004)
10.1016/J.IJROBP.2003.07.008
Early neuro-otologic effects of three-dimensional irradiation in children with primary brain tumors.
T. Merchant (2004)
10.1016/j.ijrobp.2011.09.004
Reducing xerostomia after chemo-IMRT for head-and-neck cancer: beyond sparing the parotid glands.
M. Little (2012)
10.1016/0360-3016(94)00513-3
The effect of irradiation on lung function and perfusion in patients with lung cancer.
R. Abratt (1995)
10.1016/0360-3016(93)90284-3
Phase I/II trial of accelerated fractionation in brain metastases RTOG 85-28.
W. Sause (1993)
Prediction of radiation pneumonitis: dose-volume histogram analysis in 62 patients with non-small cell lung cancer after three-dimensional conformal radiotherapy.
T. Piotrowski (2005)
10.1080/09553000210134791
Effect of dose and dose-distribution in damage to the kidney following abdominal radiotherapy
S. Köst (2002)
10.1016/j.ijrobp.2008.02.046
Small molecular inhibitor of transforming growth factor-beta protects against development of radiation-induced lung injury.
M. Anscher (2008)
10.1016/S0167-8140(01)00281-X
Rectal sequelae after conformal radiotherapy of prostate cancer: dose-volume histograms as predictive factors.
S. Wachter (2001)
10.1097/COC.0b013e3181d27080
Change in Creatinine Clearance Over Time Following Upper Abdominal Irradiation: A Dose-Volume Histogram Multivariate Analysis
V. Diavolitsis (2011)
10.1118/1.1823571
Predicting radiotherapy-induced cardiac perfusion defects.
S. Das (2005)
10.1200/JCO.2007.10.8464
Neuropsychological outcomes from a randomized trial of triple intrathecal chemotherapy compared with 18 Gy cranial radiation as CNS treatment in acute lymphoblastic leukemia: findings from Dana-Farber Cancer Institute ALL Consortium Protocol 95-01.
D. Waber (2007)
10.1016/S0090-4295(01)00940-2
Dose of radiation received by the bulb of the penis correlates with risk of impotence after three-dimensional conformal radiotherapy for prostate cancer.
B. M. Fisch (2001)
10.1016/J.IJROBP.2007.01.047
Radiation doses to structures within and adjacent to the larynx are correlated with long-term diet- and speech-related quality of life.
Ken Dornfeld (2007)
10.1016/J.IJROBP.2005.08.011
ROC curves and evaluation of radiation-induced pulmonary toxicity in breast cancer.
P. Lind (2006)
10.1016/J.IJROBP.2004.12.023
Challenges in defining radiation pneumonitis in patients with lung cancer.
Z. Koçak (2005)
10.1002/hed.20800
Postoperative intensity‐modulated radiation therapy for cancers of the paranasal sinuses, nasal cavity, and lacrimal glands: Technique, early outcomes, and toxicity
B. Hoppe (2008)
10.1016/j.ijrobp.2009.12.042
Association of P53 and ATM polymorphisms with risk of radiation-induced pneumonitis in lung cancer patients treated with radiotherapy.
M. Yang (2011)
10.1016/j.ijrobp.2009.01.079
Factors associated with neurological recovery of brainstem function following postoperative conformal radiation therapy for infratentorial ependymoma.
T. Merchant (2010)
10.1016/J.IJROBP.2005.11.046
Modeling radiation pneumonitis risk with clinical, dosimetric, and spatial parameters.
A. Hope (2006)
10.1016/J.IJROBP.2005.03.026
Correlation of dosimetric factors and radiation pneumonitis for non-small-cell lung cancer patients in a recently completed dose escalation study.
E. Yorke (2005)
10.1016/j.ijrobp.2009.04.019
Predictive factors of late radiation fibrosis: a prospective study in non-small cell lung cancer.
R. Mazeron (2010)
10.1016/J.IJROBP.2004.03.039
Orbital lymphoma: is it necessary to treat the entire orbit?
M. Pfeffer (2004)
10.1016/0360-3016(93)90398-F
Use of Veff and iso-NTCP in the implementation of dose escalation protocols.
R. Ten Haken (1993)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar